Nurofen

Nurofen is a consumer healthcare brand best known for over-the-counter pain and fever medicines containing ibuprofen. The brand was introduced in 1983 and is primarily associated with the United Kingdom, although its products have also been marketed in other European countries, South Africa, Australia and New Zealand. Nurofen became part of the Reckitt portfolio after Reckitt Benckiser acquired Boots Healthcare International in 2005 in a transaction valued at £1.93 billion. The acquisition also brought brands including Strepsils and Clearasil into the Reckitt Benckiser business. The core Nurofen range is based on ibuprofen, a non-steroidal anti-inflammatory drug used for the temporary relief of common conditions such as headache, dental pain, muscular pain, back pain, period pain, migraine symptoms, fever and cold-related discomfort. Products have been offered in several pharmaceutical forms, including conventional tablets, caplets, soft capsules and topical gels. Some formulations use ibuprofen as the free acid, while others use ibuprofen lysine. These forms differ in how quickly the medicine is absorbed and how it is presented to consumers, but they share ibuprofen as the principal analgesic ingredient. Nurofen has also developed products positioned around particular symptoms or use occasions. Examples described in reference material include Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache. Nurofen Cold & Flu includes pseudoephedrine in addition to ibuprofen in relevant markets. Nurofen Plus combines ibuprofen with codeine phosphate and is the only cited product in the range containing codeine. Because codeine is an opioid ingredient with misuse potential, Nurofen Plus has attracted additional safety and pharmacy-control attention. The brand's commercial positioning has generally been that of a widely available, mainstream non-prescription pain-relief product. Its range architecture has emphasized differences in formulation, delivery format, speed of absorption and symptom-oriented presentation. That strategy also generated regulatory and legal scrutiny, particularly in Australia, where authorities and courts concluded that several products marketed for specific types of pain did not provide a superior treatment effect for those pain types compared with other Nurofen products containing equivalent ibuprofen quantities. The Australian proceedings resulted in product-removal requirements and a substantial penalty against Reckitt Benckiser. Nurofen was reported to be the leading branded over-the-counter medicine by sales in Great Britain in 2016, with reported sales of £116.8 million for that year. The figure is time-specific and should not be treated as a current valuation or sales estimate. Today, Nurofen remains an active Reckitt pain-relief brand, with availability, formulations, regulatory status and product names varying by market. Its public profile combines strong recognition in consumer healthcare with continuing scrutiny of advertising claims, product differentiation, medicine safety and responsible use.

Nurofen was introduced in 1983 as a brand of ibuprofen-based pain-relief medicines. Its development followed the expansion of ibuprofen as a widely used non-prescription analgesic and antipyretic. From the beginning, the brand's principal proposition was straightforward consumer access to temporary relief from pain and fever, with dosage forms and packaging designed for pharmacy and retail distribution. Over time, Nurofen expanded beyond a basic ibuprofen tablet. The range came to include conventional round tablets, torpedo-shaped caplets, soft capsules and topical gel. Oral products used either ibuprofen free acid or ibuprofen lysine, and the difference in salt or formulation was associated with different absorption characteristics. Reference material cites UK Medicines and Healthcare products Regulatory Agency information indicating that ibuprofen lysine in Nurofen Tension Headache reached peak blood concentrations more quickly than the free-acid form used in Nurofen Period Pain. The brand therefore built part of its product architecture around speed, convenience and formulation choice. Nurofen also introduced symptom-oriented variants. These included products presented for back pain, period pain, migraine pain and tension headache, as well as cold and flu products containing an additional decongestant in relevant markets. Nurofen Plus added codeine phosphate to ibuprofen, creating a combination product with a different safety and misuse profile from the standard range. The tablet's two-part construction and the presence of codeine led to concern about the possibility of separating the ingredients for recreational misuse, reinforcing the need for responsible dispensing and consumer use. A major corporate turning point came in 2005, when Reckitt Benckiser acquired Boots Healthcare International for £1.93 billion. Nurofen was among the healthcare brands included in the transaction, alongside Strepsils and Clearasil. The acquisition placed Nurofen within a large international consumer-healthcare portfolio and supported its continued distribution outside the United Kingdom. The brand became particularly visible in parts of Europe, South Africa, Australia and New Zealand, although exact products and regulatory classifications differ between countries. Nurofen's marketing strategy subsequently became the subject of regulatory criticism. In Australia, consumer advocates argued that the targeted-pain products charged more for products whose active ingredient was equivalent to that of the standard range. In 2012, the Therapeutic Goods Administration upheld a complaint about representations that different Nurofen products were designed for different types of pain. The issue intensified in 2015 when the Australian Competition and Consumer Commission commenced Federal Court proceedings. The court found that the specific-pain range could mislead consumers because the products were not more effective at treating the advertised pain types than the other relevant Nurofen products. The court required removal of the products from retail sale and later imposed a penalty that was increased to A$6 million. The brand also experienced a product-safety incident in the United Kingdom in 2011. Several Nurofen Plus packs were found to contain Seroquel XR rather than the expected medicine. The Medicines and Healthcare products Regulatory Agency issued a safety alert covering three batches and instructed pharmacists to inspect packs. The product was subsequently re-released in cellophane-sealed packaging. This incident was distinct from the later advertising case: one concerned possible packaging or product substitution, while the other concerned consumer representations and product differentiation. Despite these controversies, Nurofen remained a prominent consumer-healthcare brand. Reference material reports that it was Great Britain's largest-selling branded over-the-counter medicine in 2016, with sales of £116.8 million in that year. Nurofen continues as an active Reckitt brand, with a portfolio centered on ibuprofen-based analgesics and market-specific combination products. Its history illustrates the evolution of a mass-market medicine brand from a simple active-ingredient proposition toward a segmented range, together with the regulatory responsibilities that accompany symptom-specific claims and broad retail availability.

• 2016

  Australian penalty increased to A$6 million

  [1]Nurofenen.wikipedia.org

  The Federal Court increased the penalty against Reckitt Benckiser for misleading Nurofen conduct to A$6 million.

• 2016

  Reported leading branded OTC medicine in Great Britain

  [1]Nurofenen.wikipedia.org

  Nurofen was reported as the biggest-selling branded over-the-counter medicine in Great Britain, with sales of £116.8 million for the year.

• 2015

  Australian court ruled against specific-pain marketing

  [1]Nurofenen.wikipedia.org

  The Federal Court of Australia found that the Nurofen Specific Pain range had misled consumers and ordered the products removed from retail sale within three months.

• 2012

  Australian advertising complaint upheld

  [1]Nurofenen.wikipedia.org

  Australia's medicines regulator upheld a complaint about representations distinguishing Nurofen products by pain type.

• 2011

  Nurofen Plus safety alert

  [1]Nurofenen.wikipedia.org

  Three batches of Nurofen Plus were subject to a UK safety alert after packs containing Seroquel XR were found in London stores.

• 2005

  Acquired through Boots Healthcare International transaction

  [1]Nurofenen.wikipedia.org

  Reckitt Benckiser acquired Boots Healthcare International for £1.93 billion, bringing Nurofen into its brand portfolio.

• 1983

  Nurofen introduced

  [1]Nurofenen.wikipedia.org

  The Nurofen brand was introduced as a range of ibuprofen-based pain-relief medicines.

Mainstream over-the-counter pain and fever relief, with products differentiated by dosage form, absorption characteristics, symptom occasion and, in some markets, additional active ingredients.

• Oral ibuprofen analgesic · 1983

  Nurofen tablets

  The core Nurofen offering consists of oral tablets containing ibuprofen for temporary relief of common pain and fever. Conventional tablets provide the basic mass-market format from which the wider Nurofen portfolio developed. Exact strengths, indications and pack sizes vary by country and regulatory approval.

• Fast-absorption oral ibuprofen

  Nurofen Express

  Nurofen Express refers to products positioned around convenient or faster delivery of ibuprofen, commonly using a caplet or liquid-filled format depending on the market. The brand's advertising and formulation messaging have emphasized speed of relief, though product claims are subject to local medicines and advertising rules.

• Symptom-positioned ibuprofen products

  Nurofen specific-pain range

  This range included products marketed for back pain, period pain, migraine pain and tension headache. The products cited in the Australian proceedings contained equivalent quantities of ibuprofen lysine. Australian authorities and the Federal Court concluded that the products were not more effective for the named pain types than comparable Nurofen products.

• Combination cold and flu medicine

  Nurofen Cold & Flu

  Nurofen Cold & Flu products combine ibuprofen with an additional active ingredient, including the non-sedating decongestant pseudoephedrine in the formulation described by reference material. Availability, composition and legal classification vary by market.

• Ibuprofen and codeine combination

  Nurofen Plus

  Nurofen Plus combines 200 mg of ibuprofen with 12.8 mg of codeine phosphate in the formulation described by reference material. It is the cited Nurofen product containing codeine. The opioid ingredient creates additional concerns relating to misuse, dependency, safe dosage and pharmacy controls.

• Topical ibuprofen

  Nurofen Gel

  Nurofen topical gel is applied to the skin over an area of discomfort rather than taken orally. It extends the brand into localized topical treatment while retaining ibuprofen as the relevant active ingredient. Indications and formulation details depend on the market.

• 2015

  Australian misleading specific-pain claims case

  The Australian Federal Court found that Reckitt Benckiser had misled consumers by presenting several Nurofen products as targeting specific kinds of pain when the products shared equivalent ibuprofen ingredients and were not more effective for those advertised pain categories. The products were ordered off Australian retail shelves, and the penalty was later increased to A$6 million.

  Source

• 2015

  UK review of Nurofen Express advertising

  The UK Advertising Standards Authority said it was investigating an earlier complaint concerning a Nurofen Express television advertisement alleged to imply that the medicine specifically targeted muscles in the head.

  Source

• 2011

  Nurofen Plus pack contamination or substitution incident

  Several Nurofen Plus packs found in London contained Seroquel XR, an antipsychotic medicine. The MHRA issued a safety alert covering three batches and instructed pharmacists to check stock. Reckitt Benckiser said it did not know where the medicines had been switched; sealed packaging was used when the product was re-released.

  Source

Read more

• 2015

  Withdraw Australian specific-pain productsOther

  Background

  The Australian Federal Court found that the specific-pain range could mislead consumers because products with equivalent ibuprofen quantities were not more effective for the pain types named on their packaging.

  Action taken

  The court ordered the relevant Nurofen specific-pain products to be removed from Australian retail sale within three months.

  Aftermath

  Reckitt Benckiser faced a later financial penalty, ultimately increased to A$6 million, and the case became a major example of scrutiny over symptom-specific OTC medicine marketing.

  Source

• 2005

  Bring Nurofen into the Reckitt Benckiser portfolioM&A

  Background

  Reckitt Benckiser acquired Boots Healthcare International, whose brands included Nurofen, Strepsils and Clearasil.

  Action taken

  The acquisition transferred Nurofen ownership to Reckitt Benckiser and supported its development within a global consumer-healthcare portfolio.

  Aftermath

  Nurofen continued to be marketed across the United Kingdom and selected international markets under the Reckitt group.

  Acquisition value. £1.93 billion (2005 transaction)

  Source

• 2016

  Nurofen reported as Great Britain's leading branded OTC medicine[1]Nurofenen.wikipedia.org

  Other

  Reference material identified Nurofen as the biggest-selling branded over-the-counter medicine in Great Britain in 2016, with reported sales of £116.8 million.

• 2011

  Nurofen Plus packs recalled after foreign medicines were discovered[1]Nurofenen.wikipedia.org

  Recall · Regulation

  Several packs of Nurofen Plus found in Boots stores in London contained Seroquel XR, an antipsychotic medicine, instead of the expected product. The UK medicines regulator issued a safety alert, and three batches were identified for checking. The product was later re-released in sealed packaging.

1. 1Nurofenen.wikipedia.org